MAPT and Dravet syndrome: Based on these findings and the observed differences in the immunostaining patterns of p-tau in DS compared to sAD (see AT180) at comparable Braak stages of neurofibrillary degeneration, therapy developers combining anti-Aβ and anti-tau therapies in DS should consider fine-tuning their strategies.